What are organoids? They are small, laboratory-grown cell structures that self-organize and resemble parts of real organs. Researchers use them to study human development and disease, not to replace organs.
This guide covers how organoids are made, what they are used for and where they fall short. It sits within the wider stem cell research section of this independent educational site.
Definition and structure
A review in the journal literature indexed by the US National Library of Medicine, Human organoids: a new dimension in cell biology, describes organoids as three-dimensional structures, generated under controlled culture conditions, that recapitulate development and tissue organization and resemble organs in the body.
The same review states that organoids originate from renewable tissue sources that self-organize in culture to acquire in vivo-like organ complexity. Self-organization is the central idea: the cells are given the right conditions, and they arrange themselves into layered or folded structures, rather than being assembled by hand.
The word “mini organ” is shorthand, and it can mislead. An organoid mimics selected features of one tissue. It is not a working organ and it cannot do the job of one inside the body.
The review itself came from a professional body. It records that the American Society for Cell Biology convened a task force to report on the potential, challenges, and limitations for human organoid research. The pairing of potential with limitations is a useful habit for any reader: a method can be genuinely valuable and still be early.
When reading news about organoids, a few questions help. Which cells were the starting point, what features of the tissue were actually reproduced, and was the work done only in a dish, or also in animals? Headlines about “mini brains” or “mini hearts” often compress these distinctions, and the underlying papers usually describe much narrower findings.
Cell sources
Organoids start from stem cells. According to the review, they can be generated from human cell sources, including adult tissue-specific stem cells, embryonic stem cells and induced pluripotent stem cells.
The choice of source shapes what the organoid can show. Cells from a patient with a particular condition can be used to build a model of that person’s tissue, which is why tissue banks matter. The review notes that the establishment of biobanks that distribute induced pluripotent cells from different patients with the same disease is particularly important for the study of disease.
Because pluripotent cells can be altered in the laboratory, the review also describes such biobanks as possible distribution hubs for genetically modified patient-derived tissue samples. Tools for making such changes are explained in the guide to CRISPR gene editing.
Research uses
Most uses sit in the laboratory. The review says human organoid cultures provide the potential to study human development and model disease processes with the same scrutiny and depth of analysis customary for research with nonhuman model organisms.
It gives examples. Brain organoids have been used to model genetic microcephaly, and human airway organoids have been used to model cystic fibrosis. Gut organoids have been used to identify patients who are uniquely responsive to an expensive therapy for cystic fibrosis.
Drug testing is another area. The review states that patient-derived human organoid studies may accelerate medical research, creating new opportunities for tissue engineering and regenerative medicine and generating knowledge and tools for preclinical studies, including drug development and testing.
Regulators have taken notice. In an announcement dated April 10, 2025, the US Food and Drug Administration said its animal testing requirement for monoclonal antibodies and other drugs would be reduced, refined or potentially replaced using approaches that include cell lines and organoid toxicity testing in a laboratory setting.
The case for human models
Much biomedical research relies on animals, and animal biology does not always match human biology. The review argues that organoids may overcome a number of previous limitations in research aimed at gaining mechanistic insights into human development, producing accurate models of human disease and generating patient-matched tissue sources for regenerative medicine.
It goes further on drugs, suggesting that the lack of human model systems may have contributed to the low success rate in clinical trials of pharmaceutical compounds developed in animal models. That is a hypothesis about a contributing factor, and it should not be read as a promise that organoids will fix drug development.
Cancer research offers another example. The review notes that a living biobank of breast cancer organoids captures disease heterogeneity, meaning the differences between tumours that make a single model insufficient. A collection of patient-derived organoids can hold more of that variety than a single standard cell line.
In each case the value is the same: a human-derived system that can be examined closely, repeated and compared across patients, without being placed inside a person. That is a practical research advantage. It is not evidence about what any therapy does in the body.
Limits that keep organoids in the lab
The review is direct about what organoids lack. They miss key features of a living body, such as a defined body axis, a functional immune or nervous system, or a functional vasculature.
Blood supply is the best-known problem. A review of bioengineering methods for vascularizing organoids states that the translational potential and ability to mimic complex in vivo functions of organoids are often hindered by the lack of an integrated vascular network.
The article adds that in native tissues, the vasculature functions in nutrient supply and regulates tissue homeostasis, regeneration, and organ functionality, which shows what a dish-grown structure is missing.
The same article explains the physical reason: diffusion remains efficient for smaller organoids, but it is inadequate beyond a specific size. Without vessels, oxygen and nutrients do not reach the centre of a larger structure, which limits how big and how long-lived an organoid can be.
These limits mean an organoid result is a clue, not proof. A finding in a dish still has to be tested in other systems, and eventually in people through the stages described for clinical research, before it can inform care.
Organoids and cell-based therapies
Organoids are sometimes mentioned alongside therapies, so the difference is worth stating. Organoids are mainly used to learn how tissues develop and respond to drugs. Therapies built on living cells, such as CAR T cell therapy, are a different category, with their own manufacturing and safety questions.
The review points to implantation studies for a sense of future direction. It reports that induced pluripotent cell-derived intestinal organoids that include both endoderm and mesoderm differentiate into fully vascularized guts when implanted into immune-compromised mice. That is a result in mice, and it does not show a treatment for people.
Anyone weighing a real-world treatment should rely on a licensed physician who knows their situation, and treat laboratory findings as background about how the science is developing.
Frequently asked questions
Are organoids real organs?
Show answer
No. They resemble parts of organs and lack features such as a functional immune or nervous system or a functional vasculature.
What cells are used to make organoids?
Show answer
Adult tissue-specific stem cells, embryonic stem cells and induced pluripotent stem cells are the human sources named in the review.
Why are blood vessels a problem?
Show answer
Diffusion is inadequate beyond a specific size, so larger organoids without an integrated vascular network struggle to receive oxygen and nutrients.
Can organoids replace animal testing?
Show answer
The FDA announced in April 2025 that animal testing requirements for some drugs could be reduced, refined or potentially replaced, with organoid toxicity testing among the approaches named.
